Wedbush Reiterates “Outperform” Rating for Verona Pharma plc – American Depositary Share (VRNA)

Verona Pharma plc – American Depositary Share (NASDAQ:VRNA)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a research report issued on Tuesday. They currently have a $33.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 178.48% from the stock’s current price.

Separately, Zacks Investment Research cut shares of Verona Pharma plc – American Depositary Share from a “hold” rating to a “sell” rating in a report on Friday, November 10th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Verona Pharma plc – American Depositary Share presently has an average rating of “Buy” and a consensus target price of $24.20.

Shares of Verona Pharma plc – American Depositary Share (NASDAQ VRNA) traded up $0.16 on Tuesday, reaching $11.85. 7,400 shares of the company’s stock were exchanged, compared to its average volume of 4,853. Verona Pharma plc – American Depositary Share has a twelve month low of $10.44 and a twelve month high of $17.50.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vivo Capital LLC purchased a new stake in Verona Pharma plc – American Depositary Share in the second quarter worth about $8,208,000. Tekla Capital Management LLC purchased a new stake in shares of Verona Pharma plc – American Depositary Share during the second quarter valued at approximately $3,211,000. Finally, FIL Ltd purchased a new stake in shares of Verona Pharma plc – American Depositary Share during the second quarter valued at approximately $873,000. Institutional investors and hedge funds own 40.27% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/13/wedbush-reiterates-outperform-rating-for-verona-pharma-plc-american-depositary-share-vrna.html.

Verona Pharma plc – American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Receive News & Ratings for Verona Pharma plc - American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma plc - American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply